SOR-C13

A short segment (13-mer) from the C-terminus of a paralytic peptide soricidin (accession number P0C2P6), which occurs in saliva of the Northern Short-tailed shrew (Blarina brevicauda); acts as an inhibitor of TRPV6 calcium channels and has antineoplastic activity against solid tumors.

Also Known As:

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Dugourd, D: 2 articles (01/2017 - 01/2017)
2.	Fields, N: 2 articles (01/2017 - 01/2017)
3.	Fu, S: 2 articles (01/2017 - 01/2017)
4.	Gong, J: 2 articles (01/2017 - 01/2017)
5.	Hirte, H: 2 articles (01/2017 - 01/2017)
6.	Hong, D: 2 articles (01/2017 - 01/2017)
7.	Ilenchuk, T T: 2 articles (01/2017 - 01/2017)
8.	Liu, L: 2 articles (01/2017 - 01/2017)
9.	Lutes, T: 2 articles (01/2017 - 01/2017)
10.	Nemet, A: 2 articles (01/2017 - 01/2017)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "Introduction This was an open-label, dose escalation (3 + 3 design), Phase I study of SOR-C13 in patients with advanced tumors of epithelial origin. " 01/01/2017 - "The best response was a 27% reduction in a pancreatic tumor with a 55% reduction in CA19-9 levels at 6.2 mg/kg. Conclusion SOR-C13 was safe and tolerated up to 6.2 mg/kg. The Maximal Tolerated Dose (MTD) was not established. " 01/01/2013 - "Herein, we report molecular imaging methods that demonstrate the in vivo diagnostic potential of SOR-C13 and SOR-C27 to target tumor sites in mice bearing ovarian or prostate tumors. " 01/01/2017 - "Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors." 01/01/2017 - "First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors."
2.	Urticaria (Hives) 01/01/2017 - "One Grade 3 treatment emergent adverse event, urticaria, was definitely related to SOR-C13. "

Related Drugs and Biologics

1.	Calcium Channels (Calcium Channel)
2.	SOR-C13
3.	Peptides (Polypeptides)